COVID Vaccines Yield Up to $809 for Every Dollar Invested
A recent study reveals that every dollar spent on COVID-19 vaccines returned up to $809 in economic benefits.
A recent study reveals that every dollar spent on COVID-19 vaccines returned up to $809 in economic benefits.
Groundbreaking research at Johns Hopkins reveals that cancer vaccines may effectively improve patient outcomes.
Sanofi Vaccines has been included in a multi-award DLA contract to supply pharmaceutical products valued at $19.4 million.
GlaxoSmithKline's Q2 report shows a 30% increase in profit, fueled by strong vaccine and medicine sales.
GPN Vaccines has raised $10 million to advance its Gamma-PN pneumococcal vaccine into Phase 2 trials, broadening its impact against a serious health threat.
GPN Vaccines has successfully closed a $10 million financing round to further develop Gamma-PN™, a novel serotype-independent pneumonia vaccine.
Recent findings reveal maternal vaccination against RSV is leading to fewer hospitalizations for infants.
Vaccines for RSV, COVID-19, and Influenza are now accessible to the public in Eastern Ontario.
Bavarian Nordic is providing a total of 225,000 doses of Mpox vaccine to strengthen global health response.
AstraZeneca's CEO hints at a future focus on mRNA cancer vaccines while evaluating its strategy.
Changes in vaccine recommendations and ACIP appointments leave access to new immunizations in jeopardy.
A recent study finds that medical assistants frequently engage parents on vaccines, highlighting a need for better communication training.